XML 18 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jul. 02, 2021
Jan. 01, 2021
Current assets:    
Cash and cash equivalents $ 492,462 $ 319,217
Short-term investments 854,171 887,319
Trade receivables, net 171,753 160,875
Inventory 24,982 20,973
Prepaid expenses and other current assets 49,878 57,011
Total current assets 1,593,246 1,445,395
Long-term investments 345,613 330,751
Property and equipment, net 95,133 67,384
Deferred tax assets, net 134,667 156,711
Goodwill 63,684 63,684
Other long-term assets 134,928 73,408
Total assets 2,367,271 2,137,333
Current liabilities:    
Accounts payable 20,450 23,632
Accrued compensation and benefits 48,324 51,189
Accrued clinical trial liabilities 67,075 52,251
Rebates and fees due to customers 31,197 20,683
Accrued collaboration liabilities 24,428 12,456
Other current liabilities 63,852 44,447
Total current liabilities 255,326 204,658
Long-term portion of deferred revenues 8,577 3,755
Long-term portion of operating lease liabilities 53,223 49,086
Other long-term liabilities 7,068 721
Total liabilities 324,194 258,220
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 314,822 and 311,627 at June 30, 2021 and December 31, 2020, respectively 315 312
Additional paid-in capital 2,390,654 2,321,895
Accumulated other comprehensive income 1,985 4,476
Accumulated deficit (349,877) (447,570)
Total stockholders’ equity 2,043,077 1,879,113
Total liabilities and stockholders’ equity $ 2,367,271 $ 2,137,333